Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (201-210 of 232) with videos related to

Pageof 24
Sort By:
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I TrialRan Xu, Fumiko Shimizu, Koos Hovinga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesShivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Larry V Rubinstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studyStephen I Shibata, Vincent Chung, Timothy W Synold, et al.
Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Pageof 24

Showing results (201-210 of 232) with videos related to

Sort By:
Pageof 24
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I TrialRan Xu, Fumiko Shimizu, Koos Hovinga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesShivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Larry V Rubinstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studyStephen I Shibata, Vincent Chung, Timothy W Synold, et al.
Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Pageof 24